IMS Health Holdings, Inc.NYSE
IMS Health: Not So Healthy Analytics
Darspal S Mann
Darspal S Mann
Veeva: Why We Went Long Our Former Favorite Short
Mon, Sep. 12, 11:24 AM
- IMS Health Holdings (IMS -0.7%) plans to raise $1.5B via an offering of senior notes due 2024. The offering will be issued in two tranches: one in U.S. dollars and one in Euros. Net proceeds, together with additional terms loans and cash on hand, will be used to retire certain debt associated with the Quintiles (Q -0.5%) merger.
Wed, Jul. 27, 7:03 AM
Tue, Jul. 26, 5:30 PM
- ANGI, ANTM, ARMH, AUO, AVX, BA, BAH, BOKF, CFR, CG, CMCSA, CRCM, CRI, DCIX, DHX, DPS, DX, DXYN, ENTG, ETM, EVR, FCAU, FCF, FDML, FLIR, FSV, GCI, GD, GIB, GIL, GLW, GRMN, GT, HES, HLT, HUN, I, IMS, IR, KO, LH, LL, LVLT, MDCO, MDLZ, MHO, MMYT, MO, NDAQ, NEE, NOC, NSC, NYCB, OC, PB, POL, Q, R, RES, ROK, ROL, RTIX, SALT, SEIC, SIX, SLAB, SLGN, SNAK, SO, SONS, SPG, STM, STRA, STT, SUP, SVU, TMUS, TPH, TYPE, UCBI, UFS, UMC, VLY, WCIC, WEC, WEX, WIX, WM, WOOF, WYN
Thu, May 26, 9:58 AM
Tue, May 3, 7:06 AM
- IMS Health Holdings (NYSE:IMS) and Quintiles Transnational Holdings (NYSE:Q) agree to combine in an all-stock merger of equals transaction. The merged organization will do business as Quintiles IMS Holdings (stock symbol not stated). Based on the closing prices on May 2, the joined company will sport a market cap of $17.6B and an enterprise value of more than $23B. 2015 pro forma revenue was $7.2B, non-GAAP EBITDA was $1.7B and non-GAAP unlevered free cash flow was $1.3B.
- Under the terms of the transaction, IMS Health shareholders will receive 0.384 of a share of Quintiles common stock for each IMS share. Post merger, they will own ~51.4% of the combined firm while Quintiles shareholders will own ~48.6%.
- Benefits of the deal: revenue growth to accelerate 1 - 2% by the end of year three; $100M per year in cost savings by the end of year three; accretive to non-GAAP EPS in 2017; maintains financial leverage of 4.0x and makes maximum use of both firms' tax assets. The companies intend to refinance certain debt in connection with the transaction.
- The merger should close in H2. The combined company will maintain dual headquarters in Danbury, CT and Research Triangle Park, NC. IMS Health Chairman and CEO Ari Bousbib will head the management team as Chairman and CEO. Quintiles CEO Tom Pike will be Vice Chairman.
- Both companies' management teams will host a conference call this morning at 8:00 am ET to discuss the deal.
Tue, May 3, 6:17 AM
- IMS Health (NYSE:IMS): Q1 EPS of $0.42 beats by $0.04.
- Revenue of $774M (+22.5% Y/Y) beats by $24.46M.
Fri, Feb. 26, 1:53 PM
- GlaxoSmithKline (GSK -0.9%) initiated with Hold rating and 1400p price target (-0.7% downside risk) by Cantor Fitzgerald.
- Shire plc (SHPG -0.6%) initiated with Buy rating by Cantor Fitzgerald.
- Insulet (PODD +8.7%) initiated with Sell rating and $15 (53% downside risk) price target by Empire Asset Management.
- MacroGenics (MGNX +2.2%) initiated with Equal Weight rating and $20 (29% upside) price target by Morgan Stanley.
- Biogen (BIIB +0.8%) initiated with Buy rating and $345 (30% upside) price target by Citigroup.
- Boston Scientific (BSX -0.3%) initiated with Buy rating and $21 (22% upside) price target by SunTrust Robinson Humphrey.
- Other initiations by Citigroup: Amgen (AMGN +1.1%) Neutral rating and $165 (11% upside) price target; Celgene (CELG +1.4%) Buy rating and $130 (25% upside) price target; Regeneron Pharmaceuticals (REGN) Buy rating and $480 (22% upside) price target; Alexion Pharmaceuticals (ALXN +0.1%) Neutral rating and $165 (18% upside) price target.
- IMS Health Holdings (IMS +0.2%) initiated with Outperform rating and $31 (19% upside) price target by Leerink Swann.
- Ocera Therapeutics (OCRX +5.7%) initiated with Buy rating and $10 (229% upside) price target by Brean Capital.
- Repligen (RGEN +3.8%) initiated with Buy rating and $36 (35% upside) price target by Craig-Hallum.
- Mesoblast (MESO -2.2%) initiated with Neutral rating and $5.50 (12% downside risk) price target by Chardan Capital.
- Ultragenyx Pharmaceutical (RARE +1.2%) initiated with Buy rating and $80 (29% upside) price target by Leerink Swann.
- Teva Pharmaceutical Industries (TEVA -0.2%) initiated with Outperform rating with $68-71 (21% upside from midpoint) price target by Wells Fargo.
- Medivation (MDVN +9.8%) initiated with Buy rating and $46 (28% upside) price target by Bank of America.
- Collegium Pharmaceutical (COLL -0.1%) initiated with Outperform rating and $35 (83% upside) price target by William Blair.
Wed, Feb. 3, 7:06 AM
- IMS Health (NYSE:IMS): Q4 EPS of $0.37 beats by $0.05.
- Revenue of $812M (+19.8% Y/Y) beats by $24.41M.
Tue, Feb. 2, 5:30 PM
Oct. 29, 2015, 7:09 AM
- IMS Health (NYSE:IMS): Q3 EPS of $0.38 beats by $0.06.
- Revenue of $735M (+12.0% Y/Y) misses by $6.46M.
Oct. 28, 2015, 5:30 PM
- ABC, ABMD, AET, ALKS, ALLE, ALLT, ALLY, ALU, ALXN, AMT, APD, AVT, AVY, AWI, BANC, BBW, BC, BG, BLL, BWA, BWEN, BXLT, CCE, CHTR, CLF, CME, CMS, COP, CRI, CRR, CSH, CVE, CVI, CVRR, DBD, DFT, DIN, DLPH, EME, EPD, EXAS, EXLS, FCN, FIG, FMS, GCI, GG, GLOP, GLPI, GNC, GOV, GT, GTLS, GTXI, HAR, HEES, HST, HTWR, I, IDA, IMS, INGR, IQNT, IRDM, IVZ, JAH, JCI, KEM, KERX, LDOS, LKQ, LLL, LPLA, MA, MCK, MD, MDP, MDXG, MGM, MMYT, MO, MPC, MPLX, MSCI, MTH, MTRN, MWW, NEO, NICE, NOK, NTCT, NVO, NYT, OAK, ODFL, OFC, OSK, PAG, PBI, PES, PF, PNK, POT, PPL, PX, RDS.A, RFP, RGS, RTIX, RYAM, SABR, SAN, SC, SCG, SHOO, SHW, SMP, SNE, SNMX, STM, TDY, TEVA, TFX, THRM, TPX, TWC, UAN, UBSI, UPL, VA, VICL, WRLD, WST, WWE, XEL, XYL, ZBH
Aug. 5, 2015, 4:54 PM
Jul. 31, 2015, 7:07 AM
- IMS Health (NYSE:IMS): Q2 EPS of $0.37 beats by $0.06.
- Revenue of $742M (+12.1% Y/Y) beats by $7.06M.
Jul. 30, 2015, 5:30 PM
Jul. 16, 2015, 11:42 AM
- Screen criteria: Market cap at least $500M; number of mutual fund investors at least equal to prior period; 50-day average turnover at least 400,000; annual sales at least $300M and EPS growth has accelerated the past three quarters.
- (ALKS +1%)(ALR +0.4%)(CERN +0.1%)(DVA +0.1%)(IMS +0.2%)(LLY +1%)(OMI +0.4%)(REGN +1.2%)(UNH -1.6%)(WAT +0.1%)
- This is not a list of buy/sell recommendations but rather a targeted list of stock that may be suitable for more in-depth research.
Jun. 22, 2015, 10:37 AM
- IMS Health (IMS +1.1%) and Foundation Medicine (FMI +2.9%) announce a collaboration to advance the understanding and effectiveness of precision medicines for treating cancer. The aim of the partnership is to enable IMS clients to better understand health outcomes and effectiveness and to improve care by better connecting patients to the right targeted therapies at the right time.
- The collaboration leverages IMS's library and other sources of patient-anonymous data with Foundation's knowledgebase of comprehensive cancer genomic information and insights from more than 43,000 clinical cases.
- Financial terms are not disclosed.